TCRX Tscan Therapeutics Inc
640
$8.01
$0.66
(7.61%)
| Watchers | 640 |
| 52-Wk Low | $1.93 |
| 52-Wk High | $9.09 |
| Market Cap | $369.27M |
| Volume | 111,214.00 |
| 52-Wk High | $9.09 |
| 52-Wk Low | $1.93 |
TScan Therapeutics (NASDAQ:TCRX) vs. Zura Bio (NASDAQ:ZURA) Financial AnalysisZolmax • about 1 month ago
TScan Therapeutics (NASDAQ:TCRX - Get Free Report) and Zura Bio (NASDAQ:ZURA - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two...
Share to Feed
WALTHAM, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...
This is a signal that TCRX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
This is a signal that TCRX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
TScan Therapeutics, Inc. (NASDAQ:TCRX Free Report) Stock analysts at HC Wainwright lifted their Q1 2024 earnings per share (EPS) estimates for shares of TScan Therapeutics in a...
HC Wainwright reiterated their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX Free Report) in a research report sent to investors on Thursday, Benzinga reports. The brokerage...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Fourth Quarter and Full Year 2023 Financial Results and Business DevelopmentsRelated Stocks: TCRX...
Presented updated data from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies at the Tandem Meetings of ASTCT and CIBMTR; 8/8 (100%) patients in treatment arms are...
WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...